Priveq Investment

Priveq is led by CEO Louise Nilsson, who joined the firm at its 1998 independence and has overseen investments including Carmel Pharma, CSAM Health, and Hemtex. Investment decisions are made by a partnership comprising Nilsson, founding partners Magnus Hardmeier and Henrik Westfeldt, and senior partners Mats Hjerpe, Senai Ayob, and Johanna Svensson. Each partner holds board representation across a subset of portfolio companies.

Priveq sources deals primarily through its four-decade network of sector-specialist industrial advisors and management teams in the Nordic region. The firm states it is agnostic on sector but targets profitable growth companies with strong market positions and competent management. It does not operate a proprietary sourcing platform or formal intermediary network but emphasizes long-standing relationships built across 140 portfolio-company investments.

Priveq is a direct investor only; it does not allocate to external private equity funds. The firm raises capital from Nordic and international institutional investors for its own fund vehicles, with the current Priveq Investment VII totaling SEK 3 billion, and deploys that capital exclusively into majority or significant minority equity positions in Nordic growth companies.

Priveq targets expansion- and late-stage growth buyouts, focusing on companies with minimum revenues of SEK 100 million and demonstrable profitability. It does not invest in venture-stage or pre-profit businesses. The firm's typical entry point is a generation change, a new product launch, or a geographic expansion into new markets.

Priveq does not publish an exclusion list, but its sector-agnostic mandate steers it toward companies with stable profitability rather than speculative technology or early-stage life sciences. The portfolio is concentrated in industrial technology, healthcare services, consumer goods, and software, with no known exposure to extractive industries, defense, or pure-play biotech.

Priveq is not a family office. It operates as an independent private equity manager backed by institutional investors. Its origins trace to Skandia, the Swedish insurer, which initially funded its investment operations from 1983 until Priveq spun out in 1998. The firm has since diversified its LP base to include European and American pension funds, endowments, and insurance companies.

Priveq does not advertise a formal co-investment program for external GPs. As a direct mid-market investor in the Nordic region, it typically holds board-level governance but not executive roles in its companies. It has not publicly disclosed co-investments alongside other private equity managers, but its industrial network occasionally places sector specialists on portfolio boards who are not Priveq employees.